In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y

David Collister; Neesh Pannu

doi:10.7326/ANNALS-24-01579-JC

In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y

Ann Intern Med. 2024 Sep;177(9):JC98. doi: 10.7326/ANNALS-24-01579-JC. Epub 2024 Sep 3.

Authors

David Collister¹, Neesh Pannu²

Affiliations

¹ University of Alberta and Hamilton Health Sciences, Edmonton, Alberta, and Hamilton, Ontario, Canada (D.C.).
² University of Alberta, Edmonton, Alberta, Canada (N.P.).

PMID: 39222509
DOI: 10.7326/ANNALS-24-01579-JC

Abstract

Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109-121. 38785209.

Publication types

Comment